Izazovi u laboratorijskoj dijagnostici autonomne sekrecije kortizola kod pacijenata sa adrenalnim incidentalomimaa

Diagnosis of autonomous cortisol secretion

  • Tamara Antonić Univerzitet u Beogradu - Farmaceutski fakultet, Katedra za medicinsku biohemiju
  • Ana Petrović Mucok Univerzitetski klinički centar Srbije, Klinika za endokrinologiju, Katedra za endokrinu laboratorijsku dijagnostiku
  • Aleksandra Stefanović Univerzitet u Beogradu - Farmaceutski fakultet, Katedra za medicinsku biohemiju
DOI: https://doi.org/10.5937/arhfarm72-36043
Ključne reči: adrenalni incidentalomi, kortizol, niskodozni deksametazon supresioni test

Sažetak


Adrenalni incidentalomi predstavljaju vizuelizacionim tehnikama slučajno otkrivene tumore nadbubrežne žlezde, bez prethodne sumnje na postojanje poremećaja funkcije ili bolesti nadbubrega. 80-90% adrenalnih incidentaloma predstavljaju benigne tumore, koji su u preko 70% slučaja nefunkcionalni, dok je kod oko 15% pacijenata sa benignim adrenalnim incidentalomima dokazana autonomna sekrecija kortizola. Iako su rezultati većeg broja istraživanja ukazali na veći kardiometabolički rizik kod pacijenata sa autonomnom sekrecijom kortizola, još uvek ne postoji jasan konsenzus o biohemijskim kriterijumima za postavljanje dijagnoze autonomne sekrecije kortizola kod pacijenata sa adrenalnim incidentalomima. U ovom radu su opisane osnovne prednosti i nedostaci različitih laboratorijskih testova koji sе koriste za postavljanje dijagnoze autonomne sekrecije kortizola.

Reference

Chatzellis E, Kaltsas G. Adrenal Incidentalomas. [Updated 2019 Nov 7]. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–Available from: https://www.ncbi.nlm.nih.gov/books/NBK279021/

Terzolo M, Stigliano A, Chiodini I, Loli P, Furlani L, Arnaldi G, et al. Italian Association of Clinical Endocrinologists. AME position statement on adrenal incidentaloma. Eur J Endocrinol. 2011;164(6):851-70.

Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B. Incidentally discovered adrenal masses. Endocr Rev. 1995;16(4):460-84.

Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175(2):G1-G34.

Mehdi A, Rao P, Thomas G. Our evolving understanding of primary aldosteronism. Cleve Clin J Med. 2021;88(4):221-7.

Ueland GÅ, Grinde T, Methlie P, Kelp O, Løvås K, Husebye ES. Diagnostic testing of autonomous cortisol secretion in adrenal incidentalomas. Endocr Connect. 2020;9(10):963-70.

Di Dalmazi G, Vicennati V, Garelli S, Casadio E, Rinaldi E, Giampalma E, et al. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing’s syndrome: a 15-year retrospective study. Lancet Diabetes Endocrinol. 2014;2(5):396-405.

Debono M, Bradburn M, Bull M, Harrison B, Ross RJ, Newell-Price J. Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. J Clin Endocrinol Metab. 2014;99(12):4462-70.

Chiodini I, Vainicher CE, Morelli V, Palmieri S, Cairoli E, Salcuni AS, et al. Mechanisms in endocrinology: Endogenous subclinical hypercortisolism and bone: a clinical review. Eur J Endocrinol. 2016;175(6):R265-R282.

Nieman L. Chapter 5 - Making the Diagnosis: Laboratory Testing and Imaging Studies. In: Laws ER, editor. Cushing’s Disease. United States; Endocrinology Consultation Service, National Institutes of Health, Bethesda, MD, United States: Academic Press, 2017; p. 75-90.

Chiodini I. Diagnosis and Treatment of Subclinical Hypercortisolism. J Clin Endocrinol Metab. 2011;96:1223-36.

Yanase T, Oki Y, Katabami T, Otsuki M, Kageyama K, Tanaka T, et al. New diagnostic criteria of adrenal subclinical Cushing’s syndrome: opinion from the Japan Endocrine Society. Endocr J. 2018;65(4):383-93.

Araujo-Castro M, Sampedro Núñez MA, Marazuela M. Autonomous cortisol secretion in adrenal incidentalomas. Endocrine. 2019;64(1):1-13.

Pecori Giraldi F, Ambrogio AG. Variability in laboratory parameters used for management of Cushing’s syndrome. Endocrine. 2015;50(3):580-9.

Rosano TG, Demers LM, Hillam R, Dybas MT, Leinung M. Clinical and analytical evaluation of an immunoradiometric assay for corticotropin. Clin Chem. 1995;41(7):1022-7.

Coste J, Strauch G, Letrait M, Bertagna X. Reliability of hormonal levels for assessing the hypothalamic-pituitary-adrenocortical system in clinical pharmacology. Br J Clin Pharmacol. 1994;38(5):474-9.

Nieman LK, Biller BMK, Findling JW, Newell-Price J, Savage MO, Stewart PM, et al. The Diagnosis of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93(5):1526-40.

Raff H, Raff JL, Findling JW. Late-Night Salivary Cortisol as a Screening Test for Cushing’s Syndrome. J Clin Endocrinol Metab. 1998;83(8):2681-6.

Newell-Price J, Trainer P, Perry L, Wass J, Grossman A, Besser M. A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing’s syndrome. Clin Endocrinol (Oxf). 1995;43(5):545-50.

Fischli S, Jenni S, Allemann S, Zwahlen M, Diem P, Christ ER, et al. Dehydroepiandrosterone sulfate in the assessment of the hypothalamic-pituitary-adrenal axis. J Clin Endocrinol Metab. 2008;93(2):539-42.

Labrie F, Luu-The V, Martel C, Chernomoretz A, Calvo E, Morissette J, et al. Dehydroepiandrosterone (DHEA) is an anabolic steroid like dihydrotestosterone (DHT), the most potent natural androgen, and tetrahydrogestrinone (THG). J Steroid Biochem Mol Biol. 2006;100(1-3):52-8.

Phillips AC, Carroll D, Gale CR, Lord JM, Arlt W, Batty GD. Cortisol, DHEA sulphate, their ratio, and all-cause and cause-specific mortality in the Vietnam Experience Study. Eur J Endocrinol. 2010;163(2):285-92.

Dennedy MC, Annamalai AK, Prankerd-Smith O, Freeman N, Vengopal K, Graggaber J, et al. Low DHEAS: A Sensitive and Specific Test for the Detection of Subclinical Hypercortisolism in Adrenal Incidentalomas. J Clin Endocrinol Metab. 2017;102(3):786-92.

Akehi Y, Kawate H, Murase K, Nagaishi R, Nomiyama T, Nomura M, et al. Proposed diagnostic criteria for subclinical Cushing's syndrome associated with adrenal incidentaloma. Endocr J. 2013;60(7):903-12.

Bencsik Z, Szabolcs I, Kovács Z, Ferencz A, Vörös A, Kaszás I, et al. Low dehydroepiandrosterone sulfate (DHEA-S) level is not a good predictor of hormonal activity in nonselected patients with incidentally detected adrenal tumors. J Clin Endocrinol Metab. 1996;81(5):1726-9.

Objavljeno
2022/04/28
Broj časopisa
Vol. 72 Br. Notebook 2 (2022): Arhiv za farmaciju
Rubrika
Pregledni (Revijalni) rad
Autori koji objavljuju u ovom časopisu pristaju na sledeće uslove:

  1. Autori zadržavaju autorska prava i pružaju časopisu pravo prvog objavljivanja rada i licenciraju ga "Creative Commons Attribution licencom" koja omogućava drugima da dele rad, uz uslov navođenja autorstva i izvornog objavljivanja u ovom časopisu.

  2. Autori mogu izraditi zasebne, ugovorne aranžmane za neekskluzivnu distribuciju članka objavljenog u časopisu (npr. postavljanje u institucionalni repozitorijum ili objavljivanje u knjizi), uz navođenje da je članak izvorno objavljen u ovom časopisu.

  3. Autorima je dozvoljeno i podstiču se da postave objavljeni članak onlajn (npr. u institucionalni repozitorijum ili na svoju internet stranicu) pre ili tokom postupka prijave rukopisa, s obzirom da takav postupak može voditi produktivnoj razmeni ideja i ranijoj i većoj citiranosti objavljenog članka (Vidi Efekti otvorenog pristupa).